

RESEARCH

Open Access



High rates of multidrug resistance among uropathogenic *Escherichia coli* in children and analyses of ESBL producers from Nepal

Narayan Prasad Parajuli^{1,3*}, Pooja Maharjan¹, Hridaya Parajuli¹, Govardhan Joshi¹, Deliya Paudel¹, Sujan Sayami² and Puspa Raj Khanal³

Abstract

Background: Emergence of Extended-spectrum beta-lactamase producing *Escherichia coli* causing urinary tract infections (UTI) among pediatric patients is an increasing problem worldwide. However, very little is known about pediatric urinary tract infections and antimicrobial resistance trend from Nepal. This study was conducted to assess the current antibiotic resistance rate and ESBL production among uropathogenic *Escherichia coli* in pediatric patients of a tertiary care teaching hospital of Nepal.

Methods: A total of 5,484 urinary tract specimens from children suspected with UTI attending a teaching hospital of Nepal over a period of one year were processed for the isolation of bacterial pathogens and their antimicrobial susceptibility testing. *Escherichia coli* ($n = 739$), the predominant isolate in pediatric UTI, was further selected for the detection of ESBL-production by phenotypic combination disk diffusion test.

Results: Incidence of urinary tract infection among pediatric patients was found to be 19.68% and *E. coli* (68.4%) was leading pathogen involved. Out of 739 *E. coli* isolates, 64.9% were multidrug resistant (MDR) and 5% were extensively drug resistant (XDR). Extended spectrum beta lactamase (ESBL) was detected in 288 (38.9%) of the *E. coli* isolates.

Conclusion: Alarming rate of drug resistance among pediatric uropathogens and high rate of ESBL-producing *E. coli* was observed. It is extremely necessary to routinely investigate the drug resistance among all isolates and formulate strict antibiotics prescription policy in our country.

Keywords: Urinary tract infection, Children, *E. coli*, ESBL, Nepal

Background

Urinary tract infection (UTI) is among the most common causes of febrile illness in children requiring antimicrobial treatment [1]. Worldwide, an estimated 8% of girls and 2% of boys experience at least one episode of UTI by the age of seven years and recurrence occurs in 12-30% of them within a year [2]. Pediatric UTI in many instances, remain under-diagnosed because of the absence of specific symptoms and signs, particularly in infants and young children [2, 3]. Therefore, accurate diagnosis and appropriate use

of antimicrobials for treatment and prevention of urinary tract infections (UTIs) is vital to reduce the burden and also to prevent the possible long-term consequences [4].

Escherichia coli have been recognised as the most common pathogen accounting for majority of urinary tract infections in children [5]. Antimicrobial therapy, usually of traditional antibiotics, is commonly prescribed to treat urinary tract infections in pediatric patients. However, increased rates acquired resistance in *E. coli* has made usual antibiotics less acceptable choice for empirical therapy in recent years [1]. The most common mechanism associated with acquired resistance in *E. coli* and other *Enterobacteriaceae* is the production of hydrolytic enzymes called β -lactamases [6, 7]. Extended-spectrum β -lactamase (ESBL), a major beta lactamase enzyme,

* Correspondence: narayan.parajuli@iom.edu.np

¹Department of Clinical Laboratory Services, Manmohan Memorial Medical College and Teaching Hospital, P.O.B.: 15201Swayambhu, Kathmandu, Nepal

³Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, Kathmandu, Nepal

Full list of author information is available at the end of the article

has the ability to hydrolyze oxymino-cephalosporins, and monobactams but not cephamycins or carbapenems and inhibited in-vitro by inhibitors such as clavulanic acid, sulbactam and tazobactam [8]. Since their evolution in 1983, more than 300 types of ESBLs have been identified in various members of the family *Enterobacteriaceae* and other non-enteric organisms [3, 6]. The infections associated with these ESBL producing isolates are difficult to treat because of their resistance towards beta lactam agents and also due to the emergence of co-existing resistance determinants such as aminoglycosides and fluoroquinolones [7]. Moreover, emergence of ESBL producing bacteria, particularly *E. coli* and *K. pneumoniae* causing pediatric urinary tract infections is a worldwide concern [9]. Options for the treatment of such multidrug resistant (MDR) gram negative bacterial infections are generally limited, and very few antibiotics are approved for use in children [10].

In Nepal, pediatric UTIs are usually treated empirically because of the unavailability of standard therapeutic guidelines and local susceptibility data [11, 12]. Knowledge of the etiological agent of UTIs and their antimicrobial resistance patterns in our setting may help clinicians in choosing the appropriate antimicrobial treatment. Moreover, most of the studies on pediatric urinary tract infections caused by multidrug resistant and ESBL producing bacteria have been reported from western world [10, 13], but the same from South Asian region including Nepal are scarce on the published literature [14]. In this perspective, the present study was designed to investigate the clinical isolates of multi-drug resistant and ESBL producing *Escherichia coli* causing urinary tract infections in children visiting a tertiary care teaching hospital in Nepal.

Methods

Study design and setup

A cross-sectional study was carried out for 1 year (June 2015 - May 2016) in the department of Microbiology and Pediatric Medicine, Manmohan Memorial Medical College and Teaching Hospital (MMCTH), a tertiary care hospital with 500 patient beds in Kathmandu, the capital city of Nepal. Study hospital is a referral center with medical, surgical, gynecological, pediatric, geriatric and other specialties.

Inclusion and exclusion criteria

During the study period, children up to 14 years of age presented to the pediatric outpatient department or admitted to pediatric inpatient ward with a clinical diagnosis of UTI were included. The clinical diagnosis of UTI was made by respective unit pediatrician in the presence of fever and/or any of the symptoms such painful micturition, increased frequency, burning micturition, or suprapubic pain/flank pain. Those children who had previous known history of antimicrobial therapy within 48 h prior to attending the

hospital and samples which grew more than one type of organism was considered as contaminated and hence, excluded from the study.

Laboratory methods

A total of 5,484 non-repetitive urine specimens (Mid-stream, Suprapubic, Catheter aspirated and Clean catch) representing urinary tract infections in pediatric patients (0-14 years) were processed semi-quantitatively by inoculating 0.001 ml of the specimen (by using a calibrated wire loop) onto the cystine lactose electrolyte deficient (CLED) agar for the isolation and identification of significant uropathogens [15]. The inoculated plates were incubated for 24 h at 37 °C in aerobic atmosphere. Growth of a single organism with a count of $\geq 10^5$ colony-forming units (CFU)/ml were considered to represent the infection and were identified using appropriate routine identification methods including colony morphology, Gram-stain, and an in-house set of biochemical tests [15]. *Escherichia coli*, the predominant uropathogen, was selected for the determination of antimicrobial susceptibility as well as identification of the multidrug resistant (MDR), extensively drug resistant (XDR) and extended spectrum beta lactamase (ESBL) producing isolates.

Antimicrobial susceptibility testing

The susceptibility of bacterial isolates against different antibiotics was tested by the disk diffusion method [modified Kirby-Bauer method] on Mueller Hinton agar (Hi-Media, India) following standard procedures recommended by the Clinical and Laboratory Standards Institute (CLSI), Wayne, USA [16]. Antibiotics that were tested in our study include Ampicillin (AMP 25 µg), Amoxicillin clavulanate (AMC20/10 µg), Aztreonam (30 µg) Gentamycin (GEN10µg), Ciprofloxacin (CIP5µg), Levofloxacin (LEV5µg) trimethoprim sulfamethoxazole/cotrimoxazole (COT30µg), Cephalexin (CN30 µg), Cefixime (CFM5µg), Ceftriaxone (CTR30µg), Ceftazidime (CAZ30µg), Piperacillin tazobactam (PIT 100/10 µg), Imipenem (IMP 10 µg), Meropenem (MRP 10 µg) Tigecycline (TGC30µg), and Colistin sulphate (CT10µg) (HiMedia Laboratories, India). Interpretations of antibiotic susceptibility results were made according to the zone size interpretative standards of CLSI [16]. *Escherichia coli* ATCC 25922 was used as a control organism for antibiotic susceptibility testing.

Identification of Multidrug Resistant (MDR), Extensive Drug Resistant (XDR) and potential ESBL *Escherichia coli*

MDR and XDR isolates were identified according to the combined guidelines of the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) [17]. In this study, the isolate resistant to at least one antimicrobial from three different group of first line drugs tested was

regarded as multidrug resistant (MDR). Extensively drug resistant (XDR) isolates were identified when the isolates are resistant to at least one agent in all but two or fewer antimicrobial categories (i.e., bacterial isolates remain susceptible to only one or two categories).

Isolates of *E. coli* were examined for their susceptibility to third generation cephalosporins by using Ceftazidime (30 µg) and Cefotaxime (30 µg) disks. If the zone of inhibition (ZOI) was ≤25 mm for Ceftriaxone, ≤22 mm for Ceftazidime and/or ≤27 mm for Cefotaxime, the isolate was considered a potential ESBL producer as recommended by CLSI and further tested by confirmatory methods [16].

Confirmatory test of ESBL

Isolates considered potential ESBL producers by initial screening were emulsified with nutrient broth to adjust the inoculum density equal to that of 0.5 Mac Farland turbidity standards. Combination Disk test (CDT), as recommended by the CLSI, was performed in all isolates presumed to be ESBL producers. In this test, Ceftazidime (30 µg) disks alone and in combination with clavulanic acid (Ceftazidime + clavulanic Acid, 30/10 µg) disks, were applied onto a plate of Mueller Hinton Agar (MHA) which was inoculated with the test strain and then incubated in ambient air for 16-18 h of incubation at 35 ± 2 °C. Isolate that showed increase of ≥ 5 mm in the zone of inhibition of the combination discs in comparison to that of the Ceftazidime disk alone was considered an ESBL producer [16].

Data analysis

The information regarding patient's profile and the results were entered into a computer program. Data analysis was carried out using the Statistical Package for Social Sciences [SPSS™] version 20.0 [IBM, Armonk, NY, USA] and presented in percentage base distribution. Data with p value of less than 0.05 (CI-95%) was regarded as significant.

Ethical consideration

Written approval was taken from Institutional Review Committee of Manmohan Memorial Institute of Health Sciences (MMIHS) after submitting and presenting research proposal. Written informed consent was taken

from every patient or their guardians before enrollment into the study.

Results

Patient demographics

During the study period, a total of 5,484 representative specimens of urinary tract from pediatric patients suspected with urinary tract infections were processed. Among total clinical specimens, 1079 (19.68%) were found with growth of at least one significant pathogen confirming urinary tract infection (UTI). Female (659, 61.0%) were most affected group of patients in both inpatient and outpatient department ($p < 0.005$). Maximum number of cases was found in the children of age group 1 to 4 years (Table 1). *Escherichia coli* ($n = 739$, 68.5%) was the most common organism isolated from urinary tract infections in pediatric group in this study.

Antimicrobial resistance pattern of *E. coli*

High level of drug resistance was noted in *E. coli* isolates. Among 739 *E. coli* isolated, highest resistance (87% each) were to ampicillin and cephalixin, followed by ciprofloxacin (78%), cefixime (71%) and levofloxacin (67%) respectively. Very few isolates (5%) were resistant to imipenem whereas entire strains revealed high susceptibility (100% each) towards colistin and tigecycline (Table 2).

Multidrug resistant (MDR) and Extensive drug resistant (XDR) isolates

Among total 739 *E. coli* isolates subjected for antimicrobial susceptibility testing, 480 (64.9%) isolates were found multidrug resistant (MDR) and 37 (5.0%) isolates were extensive drug resistant (XDR). MDR isolates were resistant to ampicillin (100%), amoxicillin clavulanate (84.7%), cephalixin (81.6%) and ciprofloxacin (80.6%) respectively. However, MDR isolates were susceptible towards amikacin (87%), imipenem (92%) and piperacillin tazobactam (81%). Although the number of XDR isolates was low, they were completely resistant to all antibiotics except colistin and tigecycline (Table 2).

Table 1 Pediatric patients with Urinary tract infections ($N = 1079$)

Patients with Urinary tract infections							
Age Group	Male (%)	Female (%)	p	Outpatient (%)	Inpatient (%)	p	Cc
<1	87	129	0.352	54	162	0.001	0.014
1 to 4	129	141	0.001	119	151	0.004	0.104
5 to 9	118	238	0.004	248	108	0.007	0.083
10 to 14	86	151	0.193	151	86	0.001	0.029
Total	420	659		572	507		

Cc Contingency coefficient

Table 2 Antibiotic susceptibility of MDR, XDR and ESBL *E. coli* isolates

Antibiotics	No. of resistant isolates (%)			
	Total isolates (%)	MDR (n = 480)%	XDR (n = 37)%	ESBL (n = 288)%
Ampicillin	645(87)	480(100)	37(100)	288(100)
Amoxicillin-clavulanate	355(48)	407(84.7)	37(100)	288(100)
Piperacillin-tazobactam	244(33)	91(19)	37(100)	78(27)
Cephalexin	645(87)	392(81.6)	37(100)	265(92)
Cefixime	525(71)	312(65)	37(100)	288(100)
Ceftazidime	333(45)	306(64)	37(100)	288(100)
Ceftriaxone	333(45)	306(64)	37(100)	288(100)
Aztreonam	318(43)	294(61)	37(100)	288(100)
Imipenem	37(5)	37(8)	37(100)	28(10)
Gentamycin	244(33)	130(27)	37(100)	118(41)
Amikacin	103(14)	64(13)	37(100)	52(18)
Ciprofloxacin	576(78)	387(80.6)	37(100)	225(78)
Levofloxacin	495(67)	245(51)	37(100)	155(54)
Cotrimoxazole	310(42)	158(33)	37(100)	141(49)
Tigecycline	0(0)	0(0)	0(0)	0(0)
Colistin	0(0)	0(0)	0(0)	0(0)

ESBL *E. coli* and their susceptibility pattern

Extended spectrum beta lactamase (ESBL) enzyme was detected in 288(38.9%) *E. coli* isolates. Penicillins, cephalosporins and monobactam group of antibiotics were appeared completely ineffective (100% resistance) against ESBL producers. However, ESBL producing *E. coli* strains were susceptible to reserve class of antibiotics including imipenem (90%), colistin (100%) and tigecycline (100%) (Table 2).

Discussion

To the best of our knowledge, this report represents the first description of ESBL producing uropathogenic *E. coli* involved in pediatric cases of urinary tract infections from our country, Nepal. Urinary tract infections are the most common infections in children and *E. coli* being leading pathogenic agent in these infections; it was our matter of interest. There was no previous report before this study to estimate the most common pathogen and its resistant pattern in pediatrics patients with urinary tract infection in our hospital.

The incidence of urinary tract infection based on significant bacterial growth among pediatric patients in this study was 19.6% and *E. coli* (68.5%) was the predominant pathogen. Similar rates have been previously reported from nearby hospitals [11, 12] and from studies of other countries [18–22]. Concurrently, significantly more females (61.0%) were found with UTI corroborating with other similar studies [12, 19, 20]. In our study, children of age group 1-4 years were found with highest number of UTI cases (contingency coefficient 0.104). Similar study

from nearby hospital also reported that children less than six years of age were found UTI prone [11]. Urinary tract infection was significantly more prevalent in the female children of age group 1-4 and 5-9 years and also, more inpatients were found with UTI ($p < 0.05$). The higher rates of UTI in this age group might be due to immune status, sanitation, and ascending infection with fecal flora.

The high prevalence of ESBL-producing uropathogenic *E. coli* (38.9%) among children is reported in this study. In addition, this study also documents the enhanced resistance of ESBL producing *E. coli* to other antimicrobial groups like aminoglycosides and fluoroquinolones. Indeed, variations in the prevalence rates of ESBL-producing *E. coli* isolates in children around the globe and even among different hospitals within a country have been reported. Our prevalence rate of ESBL producing *E. coli* (38.9%) is close to the findings reported by other studies in different parts of Asian region including Shettigar et al. (37.7%) from India [22], Pourakbari et al. (37%) and Rezai et al. (30.5%) from Iran [21, 23], Moore et al. (44%) from Cambodia [19] and Kizilca et al. (41.4%) from Turkey [24]. Extremely higher rates of ESBL *E. coli* have also been reported, notably by Chinnasami et al. (83%) from India [25], Masud et al. (53.8%) from Bangladesh [20] and Shah et al. (50.9%) from Pakistan [18]. The increased rate of ESBL-producing bacteria causing infection in community as well as hospital settings constitutes an undeniable trend. Worldwide, pediatric UTIs due to ESBL-producing bacteria are an important part of this problem because they limit therapeutic choices and increases morbidity of infection [26]. However, lower rates of ESBL-producing *E.*

coli were also reported, particularly from developed countries including 9.3% from USA [27], 10.2% from Korea [28], 14% from Taiwan [26], 14.1% from Lebanon [5] and 20.2% from Turkey [29]. These variations in the rate of ESBL producing strains of *E. coli* among UTI cases might be attributable to the geographical difference, local antibiotic prescribing policy, the extensive use of broad spectrum antibiotics especially third generation cephalosporins and endemicity of drug resistance pathogens in the locality.

ESBL producing bacteria causing infections in children may have various complications and adverse outcomes [30]. ESBL producers are non susceptible to aminopenicillins and ureidopenicillins as well as extended-spectrum β -lactam agents like second- and third-generation cephalosporins. Use of these agents as the first choice for the treatment of urinary tract infections may lead to the inappropriate treatment and predispose to long term renal complications [24]. Therefore, antimicrobial therapy in infections with ESBL producing organism is really challenging. Published reports showed that ESBL- producing strains causing UTI in children associated with prior hospitalization, beta-lactam therapy, catheterization, underlying co-morbidity and infancy [24].

In this study, multidrug resistant (MDR) and extensively drug resistant *E. coli* were found 64.9% and 5.0% respectively. Increasing pattern of resistance of urinary tract pathogens against common antibiotics in Nepal have also been reported by other researchers [12, 31] but MDR rates and drug resistance pattern among pediatric isolates from Nepal was not available. It is observed that ampicillin, cephalixin, ciprofloxacin and cefixime were poorly effective against uropathogenic *E. coli*. Only 13% of the isolates were found susceptible to all the antibiotics tested. Cephalosporin, the commonly prescribed antibiotic as empirical therapy in pediatric and adults, resistance to this group of antibiotics was found high. Almost 45% of *E. coli* isolates were resistant to at least one cephalosporin and monobactam. Similar rates of antimicrobial resistance was documented in the study from Bangladesh [20], Iran [32] and India [14]. However, compared to previous reports from Nepal, we observed a considerable increase in resistance against penicillins, aminoglycosides, quinolones and ceftriaxone [12, 31]. Lower rates of resistance among the pediatric isolates causing UTI have been documented in western countries [33].

Higher resistance to penicillins third generation cephalosporins in this study has been attributable to ESBL production among gram negative isolates. In ESBL producing isolates, augumentins (combined with beta lactamase inhibitor) such as amoxicillin clavulanate or piperacillin tazobactam can be used as alternative antimicrobials [34]. However, in this study, alarming state of resistance was observed among ESBL producers towards amoxicillin clavulanate (100%) and piperacillin tazobactam (27%). In

the case when UTI is caused by an ESBL producing bacteria in children, the broadest-spectrum antibiotic agents such as carbapenems are recommended [35] but they are only useful in hospitalized patients. In this study, too, carbapenems were found effective to the ESBL isolates. Nevertheless, for pediatric UTIs in our setting, cotrimoxazole, amoxicillin clavulanate, ciprofloxacin and amikacin can still be used as first line therapy. Furthermore, other non carbapenem groups of antibiotics in UTIs due to ESBL-producing strains have also been described [36, 37]. ESBL stable cephamycins, fosfomycin and nitrofurantoin were shown effective for UTIs caused by ESBL-producing strains but their clinical utility as monotherapy is controversial [38–40]. In addition, ESBLs usually confer resistance to other classes of antibiotics, such as quinolones and trimethoprim/sulfamethoxazole, therefore susceptibility testing of these agents is important [23]. In this study, entire MDR isolates were resistant to ampicillin and 33% isolates were resistant to cotrimoxazole, 19% to piperacillin tazobactam and 8% to imipenem whereas no isolates were found to be resistant to colistin and tigecycline. Similarly, all XDR isolates were resistant to most of the antimicrobials tested whereas colistin and tigecycline were the most effective regimens against XDR isolates. Similar rate of resistance has been documented by Ansari et al. [41] but their study included *E. coli* isolates from all age groups.

The level of drug resistance in uropathogenic *E. coli* among pediatric patient in this study is a serious issue. Previous reports have suggested that higher resistance is likely to be occurring in the communities with higher proportion of young children and high antibiotic consumption [42]. In Nepal, higher antimicrobial pressure for community infections and inappropriate therapeutic guidelines for pediatric patients might be attributable to this menacing scenario [12, 31]. Resistance to the broad spectrum cephalosporins, fluoroquinolones and aminoglycosides among the ESBL producing *E. coli* isolates in this study necessitates the use of carbapenem as alternative choice for pediatric UTIs. Although we found carbapenems as the most effective agent against the ESBL but the high rate of resistance from similar studies is of special concern [41]. Furthermore, the genes associated with antibiotic resistance usually reside in plasmid and may transfer antibiotic resistance to other wild strains of bacteria [20]. Therefore, evidence based therapy with broad spectrum antibiotics for serious or critical cases to prevent bacterial resistance is extremely needful. Aminoglycosides, amoxicillin clavulanate and trimethoprim sulfamethoxazole/cotrimoxazole would be useful alternatives as empirical antibiotics for children suspected with UTIs in our scenario.

Limitations of the study

This study has a number of limitations. We could not evaluate the risk factors and outcome of pediatric UTI cases in our setting. Further cohort studies with antimicrobial therapy and outcome would generate more significant results. Antimicrobial susceptibility testing by dilution methods and determination of minimum inhibitory concentration (MIC) of therapeutic antibiotics would be helpful for treatment and monitoring of the drug resistant infections. Due to unavailability of resources, we could not detect the genotype of ESBLs among *E coli* isolates. Further investigations with larger patient population and multiple centers would generate more significant ideas.

Conclusion

We found the menacing state of drug resistance in almost all of the *E coli* isolates included in this study. Childhood UTIs caused by ESBL-producing *E. coli* has been emerged as a serious problem in our setting. Aminoglycosides and carbapenems can be used as alternative regimens for serious infections caused by MDR *E coli*. Furthermore, it is extremely necessary to formulate a strict antibiotics prescription policy and prudent use antibiotics in our country.

Abbreviation

ASM: American Society for Microbiology; ATCC: American Type Culture Collection; CDT: Combined Disk Test; CLSI: Clinical and Laboratory Standard Institute; *E coli*: *Escherichia coli*; ESBL: Extended spectrum beta-lactamases; MDR: Multidrug resistant; MHA: Mueller Hinton Agar; MIC: Minimum inhibitory concentration; UTI: Urinary tract infection; XDR: Extensive drug resistant

Acknowledgements

We are deeply thankful to all the patients participating in this study. Our special thanks go to all the laboratory staffs, management and officials of Manmohan Memorial Teaching Hospital Kathmandu for providing the opportunity to carry out this research work.

Funding

No monetary funding support has been received for this study.

Availability of data and materials

The primary raw data will be made available to the interested researchers by the corresponding author of this article if requested.

Authors' contributions

NPP conceived the design of the study, reviewed the literature and performed the laboratory investigations. PM, HP and GJ performed the laboratory tests and helped in manuscript preparation. SS identified the clinical cases, DP and PRK guided the necessary laboratory tests. NPP prepared the manuscript with the guidance of PRK. All authors read the manuscript and approved.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Informed consent for publication of the research findings were taken from every patient enrolled in the study.

Ethics approval and consent to participate

This research was approved by the Institutional Review Committee of Manmohan Memorial Institute of Health Sciences (IRC MMIHS), Kathmandu,

Nepal. Letter of approval (Ref No: 005/MMIHS/2071) was obtained after submitting and presenting the proposal to the committee. Informed consent was taken from the patients or their parents before participating to the study. Data regarding personal information and infectious disease were coded and kept confidential.

Author details

¹Department of Clinical Laboratory Services, Manmohan Memorial Medical College and Teaching Hospital, P.O.B: 15201 Swayambhu, Kathmandu, Nepal.

²Department of Pediatrics, Manmohan Memorial Medical College and Teaching Hospital, Kathmandu, Nepal. ³Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, Kathmandu, Nepal.

Received: 2 November 2016 Accepted: 29 December 2016

Published online: 11 January 2017

References

- Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. *Clin Microbiol Rev.* 2005;18(2):417–22.
- Desai DJ, Gilbert B, McBride CA. Paediatric urinary tract infections: Diagnosis and treatment. *Aust Fam Physician.* 2016;45(8):558–63.
- Robinson JL, Le Saux N. Management of urinary tract infections in children in an era of increasing antimicrobial resistance. *Expert Rev Anti Infect Ther.* 2016;14(9):809–16.
- Hay AD, Sterne JA, Hood K, Little P, Delaney B, Hollingworth W, Wootton M, Howe R, MacGowan A, Lawton M, et al. Improving the Diagnosis and Treatment of Urinary Tract Infection in Young Children in Primary Care: Results from the DUTY Prospective Diagnostic Cohort Study. *Ann Fam Med.* 2016;14(4):325–36.
- Hanna-Wakim RH, Ghanem ST, El Helou MW, Khafaja SA, Shaker RA, Hassan SA, Saad RK, Hedari CP, Khinkarly RW, Hajar FM, et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. *Front Cell Infect Microbiol.* 2015;5:45.
- Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev.* 2005;18(4):657–86.
- Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. *Korean J Intern Med.* 2012;27(2):128–42.
- Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev.* 2001;14(4):933–51. table of contents.
- Sedighi I, Arabestani MR, Rahimbakhsh A, Karimitabar Z, Alikhani MY. Dissemination of extended-spectrum beta-lactamases and quinolone resistance genes among clinical isolates of uropathogenic *Escherichia coli* in children. *Jundishapur J Microbiol.* 2015;8(7):e19184.
- Uyar Aksu N, Ekinci Z, Dundar D, Baydemir C. Childhood urinary tract infections caused by ESBL-producing bacteria: Risk factors and empiric therapy. *Pediatr Int.* 2016. 0.1111/ped.13112. (Epub ahead of print).
- Rai GK, Upreti HC, Rai SK, Shah KP, Shrestha RM. Causative agents of urinary tract infections in children and their antibiotic sensitivity pattern: a hospital based study. *Nepal Med Coll J.* 2008;10(2):86–90.
- Singh SD, Madhup SK. Clinical profile and antibiotics sensitivity in childhood urinary tract infection at Dhulikhel Hospital. *KUMJ.* 2013;11(44):319–24.
- Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. *J Infect.* 2016;73(6):547–57.
- Sharma S, Kaur N, Malhotra S, Madan P, Ahmad W, Hans C. Serotyping and antimicrobial susceptibility pattern of *Escherichia coli* isolates from urinary tract infections in pediatric population in a tertiary care hospital. *J Pathog.* 2016;2016:2548517.
- Isenberg HD. *Clinical Microbiology Procedures Handbook*. 2nd edition. Washington DC: ASM press; 2004.
- Performance Standards for Antimicrobial Disk Susceptibility Tests. 2012. Clinical and Laboratory Standards Institute. 2012, M02-A11 (Approved Standard—Eleventh Edition).
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18(3):268–81.
- Shah Samin Ullah AAG, Islam Rehman Gohar: etiology and antibiotic resistance pattern of community-acquired urinary tract infections in children. *KJMS.* 2015;8(3):428.

19. Moore CE, Sona S, Poda S, Putchhat H, Kumar V, Sopheary S, Stoesser N, Bousfield R, Day N, Parry CM. Antimicrobial susceptibility of uropathogens isolated from Cambodian children. *Paediatr Int Child Health*. 2016;1–5. [Epub ahead of print].
20. Masud MR, Afroz H, Fakruddin M. Prevalence of extended-spectrum beta-lactamase positive bacteria in radiologically positive urinary tract infection. *Springer Plus*. 2014;3:216.
21. Pourakbari B, Ferdosian F, Mahmoudi S, Teymuri M, Sabouni F, Heydari H, Ashtiani MT, Mamishi S. Increase resistant rates and ESBL production between *E. coli* isolates causing urinary tract infection in young patients from Iran. *Braz J Microbiol*. 2012;43(2):766–9.
22. Shettigar SCG, Roche R, Nayak N, Anitha KB, Soans S. Bacteriological profile, antibiotic sensitivity pattern, and detection of extended-spectrum β -lactamase in the isolates of urinary tract infection from children. *J Child Health*. 2016;3(1):5.
23. Rezaei MS, Salehifar E, Rafiei A, Langae T. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* among Uropathogens of Pediatrics in North of Iran. 2015, 2015:309478
24. Kizilca O, Siraneci R, Yilmaz A, Hatipoglu N, Ozturk E, Kiyak A, Ozkok D. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. *Pediatr Int*. 2012;54(6):858–62.
25. Balaji Chinnasami SS. Kanimozhi Sadasivam, Sekar Pasupathy Pathogens Causing Urinary Tract Infection in Children and their in vitro Susceptibility to Antimicrobial Agents- A Hospital Based Study. *Biomed Pharmacol J*. 2016;9(1):7.
26. Wu CT, Lee HY, Chen CL, Tuan PL, Chiu CH. High prevalence and antimicrobial resistance of urinary tract infection isolates in febrile young children without localizing signs in Taiwan. *J Microbiol Immunol Infect*=Wei mian yu gan ran za zhi. 2016;49(2):243–8.
27. Degnan LA, Milstone AM, Diener-West M, Lee CK. Extended-spectrum beta-lactamase bacteria from urine isolates in children. *J Pediatr Pharmacol Ther*. 2015;20(5):373–7.
28. Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. *BMC Infect Dis*. 2015;15:414.
29. Dotis J, Printza N, Marneri A, Gidaris D, Papachristou F. Urinary tract infections caused by extended-spectrum betalactamase-producing bacteria in children: a matched casecontrol study. *Turk J Pediatr*. 2013;55(6):571–4.
30. Lee B, Kang SY, Kang HM, Yang NR, Kang HG, Ha IS, Cheong HI, Lee HJ, Choi EH. Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extended-spectrum beta-lactamase-producing enterobacteriaceae. *Infect Chemother*. 2013;45(4):415–21.
31. Sharma A, Shrestha S, Upadhyay S, Rijal P. Clinical and bacteriological profile of urinary tract infection in children at Nepal Medical College Teaching Hospital. *Nepal Med Coll J*. 2011;13(1):24–6.
32. Mirsoleymani SR, Salimi M, Shareghi Brojeni M, Ranjbar M, Mehtarpoor M. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009-2012). *Int J Pediatr*. 2014;2014:126142.
33. Stultz JS, Doern CD, Godbout E. Antibiotic resistance in pediatric urinary tract infections. *Curr Infect Dis Rep*. 2016;18(12):40.
34. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. *Clin Infect Dis*. 2006;42 Suppl 4:S164–172.
35. Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. *Scand J Infect Dis*. 2011;43(5):339–43.
36. Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, Choi JH, Yoo JH. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing *Escherichia coli*. *J Antimicrob Chemother*. 2014;69(10):2848–56.
37. Asakura T, Ikeda M, Nakamura A, Kodera S. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. *Int J Infect Dis*. 2014;29:91–5.
38. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infection. *Int J Antimicrob Agents*. 2012;40(6):554–6.
39. Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections. *Int J Antimicrob Agents*. 2016;48(1):56–60.
40. Lepeule R, Ruppe E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to *Escherichia coli* harboring CTX-M-15-type extended-spectrum beta-lactamase. *Antimicrob Agents Chemother*. 2012;56(3):1376–81.
41. Ansari S, Nepal HP, Gautam R, Shrestha S, Neopane P, Gurung G, Chapagain ML. Community acquired multi-drug resistant clinical isolates of *Escherichia coli* in a tertiary care center of Nepal. *Antimicrob Resist Infect Control*. 2015;4:15.
42. Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis. *BMJ*. 2016;352:i939.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

